178 related articles for article (PubMed ID: 37944087)
1. Africa Guidelines for Hepatocellular Carcinoma Buildup Process.
Abou-Alfa GK; Afihene M; Capanu M; Li Y; Chou JF; Asombang A; Alatise OI; Bounedjar A; Cunha L; Mekonnen HD; Diop PS; Elwakil R; Ali MM; Ndlovu N; Ndumbalo J; Makondi PT; Tzeuton C; Biachi de Castria T; Agyei-Nkansah AA; Balogun F; Bougouma A; Atipo Ibara BI; Jonas E; Kimani S; Kingham P; Kurrimbukus R; Hammad N; Fouad M; El Baghdady N; Servais Albert Fiacre EB; Sewram V; Spearman CW; Yang JD; Roberts LR; Abdelaziz AO
JCO Glob Oncol; 2023 Sep; 9():e2300159. PubMed ID: 37944087
[TBL] [Abstract][Full Text] [Related]
2. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
[TBL] [Abstract][Full Text] [Related]
3. Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective.
Su TH; Wu CH; Liu TH; Ho CM; Liu CJ
Clin Mol Hepatol; 2023 Apr; 29(2):230-241. PubMed ID: 36710607
[TBL] [Abstract][Full Text] [Related]
4. Systemic treatment for hepatocellular carcinoma.
Ján T; Dáša S; Igor A; Jana V
Klin Onkol; 2020; 33(5):356-361. PubMed ID: 33108880
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis.
Yau T; Hsu C; Kim TY; Choo SP; Kang YK; Hou MM; Numata K; Yeo W; Chopra A; Ikeda M; Kuromatsu R; Moriguchi M; Chao Y; Zhao H; Anderson J; Cruz CD; Kudo M
J Hepatol; 2019 Sep; 71(3):543-552. PubMed ID: 31176752
[TBL] [Abstract][Full Text] [Related]
6. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea.
Lee MJ; Chang SW; Kim JH; Lee YS; Cho SB; Seo YS; Yim HJ; Hwang SY; Lee HW; Chang Y; Jang JY
Invest New Drugs; 2021 Feb; 39(1):260-268. PubMed ID: 32749658
[TBL] [Abstract][Full Text] [Related]
7. Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective.
Hui RW; Mak LY; Cheung TT; Lee VH; Seto WK; Yuen MF
Clin Mol Hepatol; 2023 Apr; 29(2):217-229. PubMed ID: 36577426
[TBL] [Abstract][Full Text] [Related]
8. Goals and targets for personalized therapy for HCC.
Couri T; Pillai A
Hepatol Int; 2019 Mar; 13(2):125-137. PubMed ID: 30600478
[TBL] [Abstract][Full Text] [Related]
9. Advanced hepatocellular carcinoma: A regional cancer center experience of 48 cases.
Lokesh KN; Chaudhuri T; Lakshmaiah KC; Babu KG; Dasappa L; Jacob LA; Suresh Babu MC; Rudresha AH; Rajeev LK
Indian J Cancer; 2017; 54(3):526-529. PubMed ID: 29798951
[TBL] [Abstract][Full Text] [Related]
10. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
Abdel-Rahman O; Elsayed Z
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011313. PubMed ID: 31978267
[TBL] [Abstract][Full Text] [Related]
11. Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
Fung AS; Tam VC; Meyers DE; Sim HW; Knox JJ; Zaborska V; Davies J; Ko YJ; Batuyong E; Samawi H; Cheung WY; Lee-Ying R
Cancer Med; 2020 Jul; 9(13):4640-4647. PubMed ID: 32378799
[TBL] [Abstract][Full Text] [Related]
12. Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective.
Xie D; Shi J; Zhou J; Fan J; Gao Q
Clin Mol Hepatol; 2023 Apr; 29(2):206-216. PubMed ID: 36545708
[TBL] [Abstract][Full Text] [Related]
13. Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma.
Hong YM; Yoon KT; Cho M
BMC Cancer; 2021 May; 21(1):569. PubMed ID: 34006248
[TBL] [Abstract][Full Text] [Related]
14. Management of hepatocellular carcinoma.
Fitzmorris P; Shoreibah M; Anand BS; Singal AK
J Cancer Res Clin Oncol; 2015 May; 141(5):861-76. PubMed ID: 25158999
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib treatment on Chinese patients with advanced hepatocellular carcinoma: A study on prognostic factors of the viral and tumor status.
Lee SW; Lee TY; Peng YC; Yang SS; Yeh HZ; Chang CS
Medicine (Baltimore); 2019 Nov; 98(44):e17692. PubMed ID: 31689794
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.
Xia F; Wu LL; Lau WY; Huan HB; Wen XD; Ma KS; Li XW; Bie P
World J Gastroenterol; 2016 Jun; 22(23):5384-92. PubMed ID: 27340354
[TBL] [Abstract][Full Text] [Related]
18. Single center analysis of therapy and outcomes of hepatocellular carcinoma in Sub-Saharan Africa.
Sultan A; Anugwom CM; Wondifraw Z; Braimoh GA; Bane A; Debes JD
Expert Rev Gastroenterol Hepatol; 2020 Oct; 14(10):1007-1011. PubMed ID: 32730120
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology of Liver Cancer in Africa: Current and Future Trends.
Okeke E; Davwar PM; Roberts L; Sartorius K; Spearman W; Malu A; Duguru M
Semin Liver Dis; 2020 May; 40(2):111-123. PubMed ID: 31726474
[TBL] [Abstract][Full Text] [Related]
20. Regorafenib: a promising treatment for hepatocellular carcinoma.
Cerrito L; Ponziani FR; Garcovich M; Tortora A; Annicchiarico BE; Pompili M; Siciliano M; Gasbarrini A
Expert Opin Pharmacother; 2018 Dec; 19(17):1941-1948. PubMed ID: 30345837
[No Abstract] [Full Text] [Related]
[Next] [New Search]